Clinical-grade CAR-T cell manufacturing was performed in a closed system using a second-generation CD19 vector with 41BB costimulatory ... by quantitative PCR with the MACS Copycheck Kit human ...

Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...

German biotechnology company Miltenyi Biotec has said that its CAR-T therapy ... The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

The tool analyzes results from standard tests of organ function, tumor burden, and inflammation to predict whether lymphoma patients will respond to treatment.

German biotechnology company Miltenyi Biotec has said that its CAR-T therapy ... The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.